Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 229 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... February 25, 2025 FDA Approves Enzalutamide for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence December 15, 2023 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Color-Blind Groom Sees Color For First Time After Bride Surprises Him... November 9, 2021 Load more HOT NEWS News digest – dinosaur bone cancer, YouTube junk food ad ban... Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with... Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe
